2024
Farrington, N., Dubey, V., Johnson, A., Horner, I., Stevenson, A., Unsworth, J., . . . Darlow, C. A. (2024). Molecular pharmacodynamics of meropenem for nosocomial pneumonia caused by <i>Pseudomonas aeruginosa</i>.. mBio, 15(2), e0316523. doi:10.1128/mbio.03165-23DOI: 10.1128/mbio.03165-23
2022
Darlow, C. A., McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(12), 3349-3357. doi:10.1093/jac/dkac323DOI: 10.1093/jac/dkac323
Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing Comment (Journal article)
Gatermann, S., Das, S., Dubreuil, L., Giske, C. G., Kahlmeter, G., Lina, G., . . . Canton, R. (2022). Expected phenotypes and expert rules are important complements to antimicrobial susceptibility testing Comment. CLINICAL MICROBIOLOGY AND INFECTION, 28(6), 764-767. doi:10.1016/j.cmi.2022.03.007DOI: 10.1016/j.cmi.2022.03.007
Darlow, C. A., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., Jimenez-Valverde, A., . . . Hope, W. (2022). Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 77(5), 1334-1343. doi:10.1093/jac/dkac038DOI: 10.1093/jac/dkac038
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance (Journal article)
Farrington, N., McEntee, L., Johnson, A., Unsworth, J., Darlow, C., Jimenez-Valverde, A., . . . Hope, W. (2022). Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 66(4). doi:10.1128/aac.02181-21DOI: 10.1128/aac.02181-21
2021
Darlow, C. A., da Costa, R. M. A., Ellis, S., Franceschi, F., Sharland, M., Piddock, L., . . . Hope, W. (2021). Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria. PEDIATRIC DRUGS, 23(5), 465-484. doi:10.1007/s40272-021-00465-zDOI: 10.1007/s40272-021-00465-z
Darlow, C. A., Docobo-Perez, F., Farrington, N., Johnson, A., McEntee, L., Unsworth, J., . . . Hope, W. (2021). Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.. Antimicrobial Agents and Chemotherapy. doi:10.1128/aac.00293-21DOI: 10.1128/aac.00293-21
Cristinacce, A., Wright, J. G., Macpherson, M., Iaconis, J., & Das, S. (2021). Comparing probability of target attainment against <i>Staphylococcus aureus</i> for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 99(4). doi:10.1016/j.diagmicrobio.2020.115292DOI: 10.1016/j.diagmicrobio.2020.115292
Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models" (Journal article)
Das, S., Everett, M., Zalacain, M., & Hope, W. (2021). Reply to Asempa et al., "The Ongoing Challenge with NDM-Harboring <i>Enterobacteriaceae</i> in Murine Infection Models". ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(2). doi:10.1128/AAC.02249-20DOI: 10.1128/AAC.02249-20
2020
Das, S., Fitzgerald, R., Ullah, A., Bula, M., Collins, A. M., Mitsi, E., . . . Hope, W. (2021). Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 65(1). doi:10.1128/AAC.01468-20DOI: 10.1128/AAC.01468-20
Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility (Journal article)
Kahlmeter, G., Canton, R., Giske, C. G., & Turnidge, J. (2020). Re: In the name of common sense: EUCAST breakpoints and potential pitfalls. National dissemination of EUCAST guidelines is a shared responsibility. CLINICAL MICROBIOLOGY AND INFECTION, 26(12), 1692-1693. doi:10.1016/j.cmi.2020.08.008DOI: 10.1016/j.cmi.2020.08.008
Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae (Journal article)
Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-beta-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 64(11). doi:10.1128/AAC.01076-20DOI: 10.1128/AAC.01076-20
Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae. (Journal article)
Das, S., Johnson, A., McEntee, L., Farrington, N., Kirby, A., Unsworth, J., . . . Hope, W. (2020). Pharmacodynamics of the Novel Metallo-β-Lactamase Inhibitor ANT2681 in Combination with Meropenem for the Treatment of Infections Caused by NDM-Producing Enterobacteriaceae.. Antimicrob Agents Chemother, 64(11). doi:10.1128/AAC.01076-20DOI: 10.1128/AAC.01076-20
Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i> (Journal article)
Johnson, A., McEntee, L., Farrington, N., Kolamunnage-Dona, R., Franzoni, S., Vezzelli, A., . . . Hope, W. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing <i>Klebsiella pneumoniae</i>. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(6). doi:10.1128/AAC.00180-20DOI: 10.1128/AAC.00180-20
Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam (Journal article)
Li, J., Lovern, M., Riccobene, T., Carrothers, T. J., Newell, P., Das, S., . . . Tawadrous, M. (2020). Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 64(4). doi:10.1128/AAC.02105-19DOI: 10.1128/AAC.02105-19
Das, S., Zhou, D., Nichols, W. W., Townsend, A., Newell, P., & Li, J. (2020). Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 76(3), 349-361. doi:10.1007/s00228-019-02804-zDOI: 10.1007/s00228-019-02804-z
2019
Li, J., Das, S., Zhou, D., & Al-Huniti, N. (2019). Population Pharmacokinetic Modeling and Probability of Target Attainment Analyses in Asian Patients With Community-Acquired Pneumonia Treated With Ceftaroline Fosamil. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 8(5), 682-694. doi:10.1002/cpdd.673DOI: 10.1002/cpdd.673
Corey, G. R., Wilcox, M. H., Gonzalez, J., Jandourek, A., Wilson, D. J., Friedland, H. D., . . . Dryden, M. (2019). Ceftaroline fosamil therapy in patients with acute bacterial skin and skin-structure infections with systemic inflammatory signs: A retrospective dose comparison across three pivotal trials. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 53(6), 830-837. doi:10.1016/j.ijantimicag.2019.01.016DOI: 10.1016/j.ijantimicag.2019.01.016
Das, S., Li, J., Riccobene, T., Carrothers, T. J., Newell, P., Melnick, D., . . . Nichols, W. W. (2019). Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(4). doi:10.1128/AAC.02187-18DOI: 10.1128/AAC.02187-18
Li, J., Lovern, M., Green, M. L., Chiu, J., Zhou, D., Comisar, C., . . . Das, S. (2019). Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 12(2), 151-163. doi:10.1111/cts.12585DOI: 10.1111/cts.12585
Das, S., Li, J., Iaconis, J., Zhou, D., Stone, G. G., Yan, J. L., & Melnick, D. (2019). Ceftaroline fosamil doses and b breakpoints for <i>Staphylococcus aureus</i> in complicated skin and soft tissue infections. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 74(2), 425-431. doi:10.1093/jac/dky439DOI: 10.1093/jac/dky439
McEntee, L., Johnson, A., Farrington, N., Unsworth, J., Dane, A., Jain, A., . . . Hope, W. (2019). Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 63(8). doi:10.1128/AAC.00603-19DOI: 10.1128/AAC.00603-19
2018
Nichols, W. W., Stone, G. G., Newell, P., Broadhurst, H., Wardman, A., MacPherson, M., . . . Das, S. (2018). Ceftazidime-Avibactam Susceptibility Breakpoints Against Enterobacteriaceae and Pseudomonas aeruginosa.. Antimicrobial Agents and Chemotherapy, 62(11). doi:10.1128/aac.02590-17DOI: 10.1128/aac.02590-17
Dimelow, R., Wright, J. G., MacPherson, M., Newell, P., & Das, S. (2018). Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers. DRUGS IN R&D, 18(3), 221-230. doi:10.1007/s40268-018-0241-0DOI: 10.1007/s40268-018-0241-0
Nichols, W. W., Newell, P., Critchley, I. A., Riccobene, T., & Das, S. (2018). Avibactam Pharmacokinetic/Pharmacodynamic Targets. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 62(6). doi:10.1128/AAC.02446-17DOI: 10.1128/AAC.02446-17
2017
Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014) (Journal article)
Musuamba, F. T., Manolis, E., Holford, N., Cheung, S. Y. A., Friberg, L. E., Ogungbenro, K., . . . Rusten, I. S. (2017). Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014). CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 6(7), 418-429. doi:10.1002/psp4.12196DOI: 10.1002/psp4.12196
Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia (Journal article)
Riccobene, T. A., Khariton, T., Knebel, W., Das, S., Li, J., Jandourek, A., . . . Bradley, J. S. (2017). Population PK Modeling and Target Attainment Simulations to Support Dosing of Ceftaroline Fosamil in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia. JOURNAL OF CLINICAL PHARMACOLOGY, 57(3), 345-355. doi:10.1002/jcph.809DOI: 10.1002/jcph.809
Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment (Journal article)
Merdjan, H., Tarral, A., Das, S., & Li, J. (2017). Phase 1 Study Assessing the Pharmacokinetic Profile and Safety of Avibactam in Patients With Renal Impairment. JOURNAL OF CLINICAL PHARMACOLOGY, 57(2), 211-218. doi:10.1002/jcph.793DOI: 10.1002/jcph.793
2016
Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients (Journal article)
Bradley, J. S., Armstrong, J., Arrieta, A., Bishai, R., Das, S., Delair, S., . . . Zhoug, D. (2016). Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 60(10), 6252-6259. doi:10.1128/AAC.00862-16DOI: 10.1128/AAC.00862-16
2015
Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens (Journal article)
Nicolau, D. P., Siew, L., Armstrong, J., Li, J., Edeki, T., Learoyd, M., & Das, S. (2015). Phase 1 study assessing the steady-state concentration of ceftazidime and avibactam in plasma and epithelial lining fluid following two dosing regimens. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 70(10), 2862-2869. doi:10.1093/jac/dkv170DOI: 10.1093/jac/dkv170
Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects (Journal article)
Das, S., Li, J., Armstrong, J., Learoyd, M., & Edeki, T. (2015). Randomized pharmacokinetic and drug-drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects. PHARMACOLOGY RESEARCH & PERSPECTIVES, 3(5). doi:10.1002/prp2.172DOI: 10.1002/prp2.172
Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers (Journal article)
Tominaga, N., Edeki, T., Li, J., Learoyd, M., Bouw, M. R., & Das, S. (2015). Phase I study assessing the safety, tolerability, and pharmacokinetics of avibactam and ceftazidime-avibactam in healthy Japanese volunteers. JOURNAL OF INFECTION AND CHEMOTHERAPY, 21(8), 551-558. doi:10.1016/j.jiac.2015.04.006DOI: 10.1016/j.jiac.2015.04.006
2014
Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis (Journal article)
Newham, P., Ross, D., Ceuppens, P., Das, S., Yates, J. W. T., Betts, C., . . . McKay, J. S. (2014). Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-α (TNF-α) using AZD9773, an anti-TNF-α immune Fab, in murine CLP sepsis. INFLAMMATION RESEARCH, 63(2), 149-160. doi:10.1007/s00011-013-0683-3DOI: 10.1007/s00011-013-0683-3
Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential (Journal article)
Vishwanathan, K., Mair, S., Gupta, A., Atherton, J., Clarkson-Jones, J., Edeki, T., & Das, S. (2014). Assessment of the Mass Balance Recovery and Metabolite Profile of Avibactam in Humans and In Vitro Drug-Drug Interaction Potential. DRUG METABOLISM AND DISPOSITION, 42(5), 932-942. doi:10.1124/dmd.113.055335DOI: 10.1124/dmd.113.055335
Randomized, Placebo-Controlled Study to Assess the Impact on QT/QTc Interval of Supratherapeutic Doses of Ceftazidime-Avibactam or Ceftaroline Fosamil-Avibactam (Journal article)
Das, S., Armstrong, J., Mathews, D., Li, J., & Edeki, T. (2014). Randomized, Placebo-Controlled Study to Assess the Impact on QT/QTc Interval of Supratherapeutic Doses of Ceftazidime-Avibactam or Ceftaroline Fosamil-Avibactam. JOURNAL OF CLINICAL PHARMACOLOGY, 54(3), 331-340. doi:10.1002/jcph.199DOI: 10.1002/jcph.199
2013
Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors (Journal article)
Schwartz, G. K., Carvajal, R. D., Midgley, R., Rodig, S. J., Stockman, P. K., Ataman, O., . . . Shapiro, G. I. (2013). Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors. INVESTIGATIONAL NEW DRUGS, 31(2), 370-380. doi:10.1007/s10637-012-9825-7DOI: 10.1007/s10637-012-9825-7
2012
Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-<i>α</i> polyclonal fragment antibody AZD9773 in patients with severe sepsis (Journal article)
Yates, J. W. T., Das, S., Mainwaring, G., & Kemp, J. (2012). Population pharmacokinetic/pharmacodynamic modelling of the anti-TNF-<i>α</i> polyclonal fragment antibody AZD9773 in patients with severe sepsis. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 39(6), 591-599. doi:10.1007/s10928-012-9270-4DOI: 10.1007/s10928-012-9270-4
A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock (Journal article)
Morris, P. E., Zeno, B., Bernard, A. C., Huang, X., Das, S., Edeki, T., . . . Bernard, G. R. (2012). A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock. CRITICAL CARE, 16(1). doi:10.1186/cc11203DOI: 10.1186/cc11203
2011
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors (Journal article)
Boss, D. S., Witteveen, P. O., van der Sar, J., Lolkema, M. P., Voest, E. E., Stockman, P. K., . . . Schellens, J. H. (2011). Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. ANNALS OF ONCOLOGY, 22(2), 431-437. doi:10.1093/annonc/mdq344DOI: 10.1093/annonc/mdq344
